(firstQuint)TOL-463 Phase 2 Study for Vaginitis.

 This is a Phase II randomized single blind safety and efficacy study of TOL-463, administered to female adults to treat vaginitis.

 Participants will be randomly assigned (1:1) to dose TOL-463 Gel or TOL-463 Insert.

 Study medication will be administered vaginally, once nightly for seven days.

 The duration of the study for each participant will be approximately 21-30 days.

.

 TOL-463 Phase 2 Study for Vaginitis@highlight

This is a Phase II study designed to assess the safety and efficacy of an investigational product, TOL-463, to treat vaginitis.

